Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at the American College of Rheumatology (ACR) Convergence 2026

Artiva Biotherapeutics announced one oral and two poster presentations at ACR Convergence 2026 (November 6-11, Orlando) featuring updated clinical data for AlloNK (AB-101) plus rituximab in autoimmune diseases. The oral presentation covers at least 20 refractory RA patients, 11 Sjögren disease patients and at least 5 systemic sclerosis patients from the Phase 2a basket trial with at least six months of follow-up, with posters citing deep B-cell depletion comparable to CD19 CAR T and a favorable safety profile across a 60-patient cohort. Artiva will host a webcast on November 9, 2026 at 8:15 am EST including in-depth analysis of at least 10 refractory RA patients who would meet key eligibility criteria for its Phase 3 registrational trial, which the company plans to initiate in the second half of 2026.

•0mo ago

Artiva Biotherapeutics Highlights Updated AlloNK® Data in Sjögren Disease Presented at the 17th International Symposium on Sjögren’s Disease (ISSjD 2026)

Artiva presented updated Phase 2a data for AlloNK plus rituximab in Sjögren disease at ISSjD 2026, showing clinically meaningful improvements in 11 patients with longstanding, highly active disease at six months. ClinESSDAI improved 6.9 points and ESSPRI improved 3.5 points, both exceeding minimally clinically important thresholds; mean stimulated salivary flow rose from 0.4 to 1.1 mL/min, crossing the normal-salivation threshold. Safety across 73 basket-study patients showed no CRS, ICANS, graft-versus-host disease or hypogammaglobulinemia, supporting outpatient administration; 11% had serious adverse events, with two unrelated serious infections. Artiva plans to initiate a Phase 3 registrational trial of AlloNK in refractory rheumatoid arthritis in the second half of 2026.

•1mo ago

Artiva Biotherapeutics Announces Oral Presentation of AlloNK® Clinical Data at the 17th International Symposium on Sjögren’s Disease

Artiva Biotherapeutics will present updated clinical data on AlloNK (AB-101) in an oral presentation at the 17th International Symposium on Sjögren's Disease, held September 29 to October 2 in Paris. The abstract, presented October 1 by Guillermo J. Valenzuela, M.D., covers AB-101 combined with rituximab generating robust efficacy responses in 11 patients with Sjögren disease. AlloNK is Artiva's lead asset; the company is initiating a Phase 3 registrational trial in refractory rheumatoid arthritis in the second half of 2026 and is also evaluating AlloNK in Sjögren disease, systemic sclerosis, and myositis.

•1mo ago

Artiva Biotherapeutics Provides Update on Planned AlloNK® Data Disclosures and Development Milestones for the Remainder of 2026

Artiva Biotherapeutics is initiating a Phase 3 registrational trial in the second half of 2026 evaluating AlloNK plus rituximab versus rituximab alone in approximately 150 patients with refractory rheumatoid arthritis, with topline results expected by the end of 2028. Updated Phase 2a basket-trial data are expected in H2 2026 from at least 20 refractory RA patients with at least six months of follow-up — including at least 10 who would meet Phase 3 eligibility criteria — plus at least 10 Sjögren disease and at least five systemic sclerosis patients. The trial targets an ACR50 response rate greater than 50% versus roughly 20% expected with rituximab alone, and Artiva has FDA alignment on a single registrational trial along with RMAT designation for AlloNK. Management notes cash runway is expected to extend into 2029, beyond the planned topline readout, though this release contains no new clinical efficacy data.

•1mo ago

Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Artiva reported a Q2 net loss of $25.0 million, or $(0.63) per share, while ending the quarter with a strong cash position of $349.4 million following a recent $300 million public offering. The company achieved a key regulatory milestone with the FDA granting RMAT designation to AlloNK plus rituximab for refractory rheumatoid arthritis, facilitating a Phase 3 registrational trial slated to begin in the second half of 2026. Recent Phase 2a data highlighted a 71% ACR50 response rate in refractory RA patients with a favorable safety profile supporting outpatient administration.

•2mo ago

Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today

Artiva Biotherapeutics presented positive Phase 2a data for its lead asset AlloNK at EULAR 2026, showing a 71% ACR50 response rate at six months in refractory rheumatoid arthritis patients. The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to AlloNK plus rituximab for refractory RA, supporting the company's planned registrational strategy and providing access to expedited development benefits. Safety data across 55 patients showed a favorable profile with no cytokine release syndrome or treatment discontinuations due to adverse events, supporting the potential for outpatient administration.

•4mo ago

Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

Artiva Biotherapeutics reported positive initial clinical data for AlloNK® (AB-101) in refractory rheumatoid arthritis (RA) and other autoimmune diseases, with a 71% ACR50 response rate in RA patients with at least six months of follow-up. The treatment regimen demonstrated tolerability results supportive of outpatient administration in community rheumatology settings, with no CRS, ICANS, or treatment discontinuations related to AlloNK reported. Artiva achieved FDA alignment on a single Phase 3 registrational trial design in refractory RA, with plans to initiate the trial in the second half of 2026. The company will present multiple abstracts at EULAR 2026, including a late-breaking oral presentation on AlloNK clinical efficacy in refractory RA, Sjögren disease, and systemic sclerosis.

•5mo ago